Cargando…
Critical appraisal of ticagrelor in the management of acute coronary syndrome
Ticagrelor is a novel P2Y(12) receptor antagonist which, like clopidogrel and prasugrel, functions by blocking adenosine diphosphate-mediated platelet aggregation. However, unlike the aforementioned agents, the binding of ticagrelor to this receptor is reversible. Ticagrelor is also believed to medi...
Autores principales: | Nawarskas, James J, Snowden, Stanley S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253754/ https://www.ncbi.nlm.nih.gov/pubmed/22241944 http://dx.doi.org/10.2147/TCRM.S19835 |
Ejemplares similares
-
Prasugrel versus ticagrelor for acute coronary syndrome patients undergoing percutaneous coronary intervention: A critical appraisal of randomized controlled trials
por: Almas, Talal, et al.
Publicado: (2022) -
Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010) -
Dyspnoea management in acute coronary syndrome patients treated with ticagrelor
por: Parodi, Guido, et al.
Publicado: (2015) -
Metabolism of ticagrelor in patients with acute coronary syndromes
por: Adamski, Piotr, et al.
Publicado: (2018) -
A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases
por: Tao, Luyuan, et al.
Publicado: (2022)